Background
Nysnö has its roots in the Swedish Network for Psychedelic Science, founded in 2016. The work there led to Sweden's first scientific conference on psychedelic psychiatry in 2018, and to the approval in 2020 of the first Swedish clinical study of psilocybin for depression.
Nysnö took shape in 2021 as the next step towards a responsible integration of psychedelic treatment models in Sweden: retreat programs, education and a contribution to research and public debate.